Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use

References

• Wang D, Tindall DJ. Androgen action during prostate carcinogenesis. Methods Mol Biol 2011;776:25–44.
   PubMedGoogle Scholar
• John EM, Stern MC, Sinha R, Koo J. Meat consumption, cooking practices, meat mutagens, and risk of prostate cancer. Nutr Cancer 2011;63:525–37.
   PubMed Web of Science ®Google Scholar
• Schwingshackl L, Hoffmann G. Adherence to Mediterranean diet and risk of cancer: a systematic review and meta-analysis of observational studies. Int J Cancer 2014;135:1884–97.
   PubMed Web of Science ®Google Scholar
• Wong YY, Hyde Z, McCaul KA, Yeap BB, Golledge J, Hankey GJ, Flicker L. In older men, lower plasma 25-hydroxyvitamin D is associated with reduced incidence of prostate, but not colorectal or lung cancer. PLoS One 2014;9:e99954.
   Google Scholar
• Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009;301:52–62.
   PubMed Web of Science ®Google Scholar
• Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549–56.
   PubMed Web of Science ®Google Scholar
• Veitonmäki T, Tammela TL, Auvinen A, Murtola TJ. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 2013;49:938–45.
   PubMed Web of Science ®Google Scholar
• Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst 2013;105:719–25.
   PubMedGoogle Scholar
• Yassa M, Saliou M, De Rycke Y, Hemery C, Henni M, Bachaud JM, et al. Male pattern baldness and the risk of prostate cancer. Ann Oncol 2011;22:1824–7.
   PubMed Web of Science ®Google Scholar
• Giles GG, Severi G, Sinclair R, English DR, McCredie MR, Johnson W, et al. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev 2002;11:549–53.
   PubMed Web of Science ®Google Scholar
• Muller DC, Giles GG, Sinclair R, Hopper JL, English DR, Severi G. Age-dependent associations between androgenetic alopecia and prostate cancer risk. Cancer Epidemiol, Biomarkers Prev 2013;22:209–15.
   PubMed Web of Science ®Google Scholar
• Amoretti A, Laydner H, Bergfeld W. Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis. J Am Acad Dermatol 2013;68:937–43.
   PubMed Web of Science ®Google Scholar
• Zhou CK, Littman AJ, Levine PH, Hoffman HJ, Cleary SD, White E, Cook MB. Male pattern baldness in relation to prostate cancer risks: an analysis in the VITamins And Lifestyle (VITAL) cohort study. Prostate 2015;75:415–23.
   PubMed Web of Science ®Google Scholar
• Zhou CK, Pfeiffer RM, Cleary SD, Hoffman HJ, Levine PH, Chu LW, et al. Relationship between male pattern baldness and the risk of aggressive prostate cancer: an analysis of the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol 2015;33:419–25.
   PubMed Web of Science ®Google Scholar
• Bassett JK, Severi G, Hodge AM, Baglietto L, Hopper JL, English DR, et al. Dietary intake of B vitamins and methionine and prostate cancer incidence and mortality. Cancer Causes Control 2012;23:855–63.
   PubMed Web of Science ®Google Scholar
• Hultdin J, Van Guelpen B, Bergh A, Hallmans G, Stattin P. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int J Cancer 2005;113:819–24.
   PubMed Web of Science ®Google Scholar
• Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, Smith GD, et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19:1632–42.
   PubMed Web of Science ®Google Scholar
• Wang L, Sesso HD, Glynn RJ, Christen WG, Bubes V, Manson JE, et al. Vitamin E and C supplementation and risk of cancer in men: posttrial follow-up in the Physicians' Health Study II randomized trial. Am J Clin Nutr 2014;100:915–23.
   PubMed Web of Science ®Google Scholar
• Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 2006;98:245–54.
   PubMed Web of Science ®Google Scholar
• Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, et al. Plasma vitamin D and prostate cancer risk: results from the selenium and vitamin E cancer prevention trial. Cebp 2014;23:1494–504.
   Google Scholar
• Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004;108:104–8.
   PubMed Web of Science ®Google Scholar
• Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA. Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 2007;16:2784–6.
   PubMed Web of Science ®Google Scholar
• Weinstein SJ, Wright ME, Lawson KA, Snyder K, Männistö S, Taylor PR, et al. Serum and dietary vitamin E in relation to prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:1253–9.
   PubMed Web of Science ®Google Scholar
• Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the alpha-tocopherol beta-carotene cancer prevention study. Am J Clin Nutr 1995;62:1427S–30.
   PubMed Web of Science ®Google Scholar
• Beilby J, Ambrosini GL, Rossi E, de Klerk NH, Musk AW. Serum levels of folate, lycopene, β-carotene, retinol and vitamin E and prostate cancer risk. Eur J Clin Nutr 2010;64:1235–8.
   PubMed Web of Science ®Google Scholar
• Lawson KA, Wright ME, Subar A, Mouw T, Hollenbeck A, Schatzkin A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 2007;99:754–64.
   PubMed Web of Science ®Google Scholar
• Stevens VL, McCullough ML, Diver WR, Rodriguez C, Jacobs EJ, Thun MJ, et al. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control 2005;16:643–50.
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, et al. Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2012;308:1871–80.
   PubMed Web of Science ®Google Scholar
• Bhindi B, Margel D, Hamilton RJ, Fernandes KA, Trottier G, Hersey KM, et al. The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy. Urology 2014;84:1073–80.
   PubMed Web of Science ®Google Scholar
• Wang X, Lin YW, Wu J, Zhu Y, Xu XL, Xu X, et al. Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk. World J Surg Oncol 2014;12:304.
   PubMed Web of Science ®Google Scholar
• Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res 2015;21:756–62.
   PubMed Web of Science ®Google Scholar
• Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL, et al. Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. Br J Cancer 2014;111:1421–31.
   PubMed Web of Science ®Google Scholar